Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (884) 884
Publication (82) 82
Book Review (9) 9
Conference Proceeding (3) 3
Book / eBook (2) 2
Book Chapter (2) 2
Magazine Article (2) 2
Data Set (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (837) 837
hiv infections - drug therapy (578) 578
dideoxynucleosides - adverse effects (568) 568
male (432) 432
anti-hiv agents - adverse effects (416) 416
female (392) 392
dideoxynucleosides - therapeutic use (387) 387
adult (355) 355
index medicus (354) 354
infectious diseases (302) 302
anti-hiv agents - therapeutic use (281) 281
middle aged (276) 276
abacavir (272) 272
hiv (222) 222
dideoxynucleosides - administration & dosage (212) 212
reverse transcriptase inhibitors - adverse effects (211) 211
immunology (190) 190
pharmacology & pharmacy (185) 185
drug therapy, combination (172) 172
lamivudine - therapeutic use (157) 157
reverse transcriptase inhibitors - therapeutic use (154) 154
anti-hiv agents - administration & dosage (146) 146
antiretroviral therapy (135) 135
drug combinations (134) 134
lamivudine - adverse effects (126) 126
lamivudine - administration & dosage (119) 119
hla-b antigens - genetics (118) 118
tenofovir (116) 116
virology (116) 116
treatment outcome (115) 115
lamivudine (113) 113
cd4 lymphocyte count (111) 111
drug hypersensitivity - genetics (111) 111
viral load (104) 104
antiviral agents (103) 103
adenine - analogs & derivatives (101) 101
hiv-1 (101) 101
hiv infections - virology (100) 100
hiv infection (97) 97
drug therapy (96) 96
hiv infections - complications (91) 91
zidovudine (89) 89
aged (88) 88
therapy (88) 88
risk factors (87) 87
aids (85) 85
zidovudine - therapeutic use (84) 84
pharmacogenetics (82) 82
microbiology (80) 80
hiv infections - immunology (77) 77
antiretroviral therapy, highly active - adverse effects (75) 75
zidovudine - adverse effects (74) 74
drug hypersensitivity - etiology (73) 73
hiv-1 - drug effects (71) 71
reverse transcriptase inhibitors - administration & dosage (70) 70
dideoxynucleosides - pharmacology (68) 68
human immunodeficiency virus--hiv (68) 68
adenine - therapeutic use (65) 65
antiretroviral therapy, highly active (65) 65
reverse-transcriptase inhibitors (65) 65
adolescent (64) 64
medicine, general & internal (64) 64
hypersensitivity (63) 63
hiv-infected patients (62) 62
zidovudine - administration & dosage (62) 62
drug hypersensitivity (61) 61
aids/hiv (60) 60
antiretroviral drugs (60) 60
emtricitabine (60) 60
research (60) 60
efavirenz (59) 59
animals (57) 57
health aspects (57) 57
safety (57) 57
myocardial-infarction (56) 56
protease inhibitors (56) 56
benzoxazines (54) 54
drug administration schedule (54) 54
adenine - adverse effects (53) 53
association (53) 53
dideoxynucleosides (52) 52
hiv protease inhibitors - therapeutic use (52) 52
rna, viral - blood (52) 52
clinical trials as topic (51) 51
drug hypersensitivity - immunology (51) 51
prospective studies (51) 51
dideoxynucleosides - pharmacokinetics (50) 50
highly active antiretroviral therapy (50) 50
hla-b-asterisk-5701 (50) 50
organophosphonates - therapeutic use (50) 50
retrospective studies (50) 50
risk (50) 50
deoxycytidine - analogs & derivatives (49) 49
human immunodeficiency virus (49) 49
care and treatment (48) 48
drugs (47) 47
clinical trials (46) 46
young adult (46) 46
antiretroviral therapy, highly active - methods (45) 45
genotype (45) 45
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (842) 842
German (18) 18
Spanish (11) 11
French (8) 8
Italian (3) 3
Chinese (2) 2
Russian (2) 2
Japanese (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
by Friis-Møller, Nina and Ryom, Lene and Smith, Colette and Weber, Rainer and Reiss, Peter and Dabis, F and de Wit, Stephane and Monforte, Antonella D.'Arminio and Kirk, Ole and Fontas, Eric and Sabin, Caroline and Phillips, Anew and Lundgren, Jens and Law, Matthew and DAD Study Grp and D:A:D study group
European journal of preventive cardiology, ISSN 2047-4881, 2016, Volume 23, Issue 2, pp. 214 - 223
With the aging of the population living with HIV, the absolute risk of cardiovascular disease (CVD) is increasing. There is a need to further facilitate the... 
epidemiology | AIDS | CVD risk prediction | HIV | T-CELL COUNT | PROJECT | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | DEATH | RECLASSIFICATION | INDIVIDUAL ANTIRETROVIRAL DRUGS | INFECTED PATIENTS | COHORT | ASSOCIATION | Blood Pressure | Genetic Predisposition to Disease | Prospective Studies | Age Factors | Risk Assessment | Lipoproteins, HDL - blood | Cholesterol - blood | HIV Infections - epidemiology | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Models, Statistical | HIV Protease Inhibitors - therapeutic use | Smoking - epidemiology | Diabetes Mellitus - epidemiology | Sex Factors | Cardiovascular Diseases - epidemiology | Adult | Female | Dideoxynucleosides - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
by Grace A. McComsey and Douglas Kitch and Eric S. Daar and Camlin Tierney and Nasreen C. Jahed and Pablo Tebas and Laurie Myers and Kathleen Melbourne and Belinda Ha and Paul E. Sax
The Journal of Infectious Diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
by Smith, Kimberly Y and Patel, Parul and Fine, Derek and Bellos, Nicholaos and Sloan, Louis and Lackey, Philip and Kumar, Princy N and Sutherland-Phillips, Denise H and Vavro, Cindy and Yau, Linda and Wannamaker, Paul and Shaefer, Mark S and HEAT Study Team
AIDS, ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for... 
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | tenofovir | antiretroviral therapy | NAIVE HIV-1-INFECTED PATIENTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | lopinavir | ritonavir | RENAL-FAILURE | abacavir | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | FANCONI-SYNDROME | lamivudine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging
by Edwin Leeansyah and Paul U. Cameron and Ajantha Solomon and Surekha Tennakoon and Pushparaj Velayudham and Maelenn Gouillou and Tim Spelman and Anna Hearps and Christopher Fairley and Anna B. Pierce and Jude Armishaw and Suzanne M. Crowe and David A. Cooper and Kersten K. Koelsch and Jun-Ping Liu and John Chuah and Sharon R. Lewin
The Journal of Infectious Diseases, ISSN 0022-1899, 4/2013, Volume 207, Issue 7, pp. 1157 - 1165
Background. Human immunodeficiency virus (HIV)-infected patients on combination active antiretroviral therapy (cART) are at increased risk of age-related... 
T lymphocytes | HIV/AIDS | Telomeres | Antiretrovirals | HIV | Final causes | Cell lines | Nucleosides | Reverse transcriptase inhibitors | Carts | Disease risks | telomerase | aging | HIV infection | antiretroviral therapy | telomere | INFECTIOUS DISEASES | HUMAN HL60 CELLS | ANTIRETROVIRAL NUCLEOSIDE | ALZHEIMERS-DISEASE | LENGTH | MICROBIOLOGY | IMMUNOLOGY | CANCER | CD8(+) T-CELLS | IN-VITRO | THERAPY | INFECTION | UP-REGULATION | Humans | Middle Aged | Aging - drug effects | Antiretroviral Therapy, Highly Active - adverse effects | Male | Telomere - drug effects | Case-Control Studies | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Young Adult | Telomere Shortening | Adenine - adverse effects | HIV Infections - pathology | Time Factors | Polymerase Chain Reaction | Adult | Deoxycytidine - adverse effects | Female | Telomerase - metabolism | Dideoxynucleosides - adverse effects | Emtricitabine | Adenine - analogs & derivatives | Leukocytes, Mononuclear - drug effects | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Risk Factors | Cells, Cultured | Organophosphonates - adverse effects | HIV - pathogenicity | Enzyme Activation - drug effects | Regression Analysis | Telomere - enzymology | HIV Infections - drug therapy | Leukocytes, Mononuclear - enzymology | Telomerase - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Complications and side effects | Demographic aspects | Physiological aspects | Aging | Research | Telomerase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study
by Hans-Jürgen Stellbrink and Chloe Orkin and Jose Ramon Arribas and Juliet Compston and Jan Gerstoft and Eric Van Wijngaerden and Adriano Lazzarin and Giuliano Rizzardini and Herman G. Sprenger and John Lambert and Gunta Sture and David Leather and Sara Hughes and Patrizia Zucchi and Helen Pearce and ASSERT Study Grp and ASSERT Study Group
Clinical Infectious Diseases, ISSN 1058-4838, 10/2010, Volume 51, Issue 8, pp. 963 - 972
Background. Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few... 
HIV/AIDS | Body mass index | Antiretrovirals | Hip fractures | HIV | Lumbar spine | Bones | AIDS | Bone density | Biological markers | Hip | WOMEN | MINERAL DENSITY | MYOCARDIAL-INFARCTION | NAIVE PATIENTS | MEN | ANTIRETROVIRAL THERAPY | COHORT | PREVALENCE | UMCG Approved | OSTEOPOROSIS | HYPERSENSITIVITY | INFECTIOUS DISEASES | EFFICACY | MICROBIOLOGY | IMMUNOLOGY | NAIVE | EVOLUTION | OSTEOPENIA | Bone and Bones - pathology | Lamivudine - administration & dosage | Bone Density - physiology | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Adenine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Europe | Organophosphonates - adverse effects | Absorptiometry, Photon | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Bone and Bones - physiopathology | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009
by Abgrall, S and Ingle, S. M and May, M. T and Cornish, R and Costagliola, D and Mercie, P and Cavassini, M and Reekie, J and Samji, H and Gill, M. J and Crane, H. M and Tate, J and Sterling, T. R and Antinori, A and Reiss, P and Saag, M. S and Mugavero, M. J and Phillips, A and Manzardo, C and Wasmuth, J. C and Stephan, C and Guest, J. L and Sirvent, J. L. G and Sterne, J. A. C and Antiretroviral Therapy Cohort Coll and Antiretroviral Therapy Cohort Collaboration (ART-CC)
AIDS (London, England), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
To estimate the incidence of and risk factors for modifications to first antiretroviral therapy (ART) regimen, treatment interruption and death. A total of 21... 
HIV/AIDS | MORTALITY | FRENCH-HOSPITAL-DATABASE | INFECTIOUS DISEASES | competing-risk method | VIROLOGICAL TREATMENT FAILURE | survival | AIDS | COMPETING RISKS | IMMUNOLOGY | DISCONTINUATION | switch | antiretroviral | VIROLOGY | RECOMMENDATIONS | ACTIVE ANTIRETROVIRAL THERAPY | interruption | INFECTED PATIENTS | COHORT | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study
by Post, Frank A and Moyle, Graeme J and Stellbrink, Hans Jürgen and Domingo, Pere and Podzamczer, Daniel and Fisher, Martin and Norden, Anthony G and Cavassini, Matthias and Rieger, Armin and Khuong-Josses, Marie-Aude and Branco, Teresa and Pearce, Helen C and Givens, Naomi and Vavro, Cindy and Lim, Michael L
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 49 - 57
Background: Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have... 
HIV-1 | Efficacy | Abacavir/lamivudine | Tenofovir/emtricitabine | Cardiovascular | Renal | ABACAVIR | tenofovir/emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | THYMIDINE ANALOG | TENOFOVIR DF | RISK | IMMUNOLOGY | cardiovascular | efficacy | abacavir/lamivudine | HIV-INFECTED PATIENTS | renal | REVERSE-TRANSCRIPTASE INHIBITORS | THERAPY | CHRONIC KIDNEY-DISEASE | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Glomerular Filtration Rate - drug effects | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | beta 2-Microglobulin - urine | Benzoxazines - adverse effects | Treatment Outcome | Retinol-Binding Proteins - urine | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
by Walmsley, Sharon L and Antela, Antonio and Clumeck, Nathan and Duiculescu, Dan and Eberhard, Andrea and Gutiérrez, Felix and Hocqueloux, Laurent and Maggiolo, Franco and Sandkovsky, Uriel and Granier, Catherine and Pappa, Keith and Wynne, Brian and Min, Sherene and Nichols, Garrett and SINGLE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
There has been remarkable improvement in primary antiretroviral therapy (ART) for human immunodeficiency virus type 1 infection over the past 15 years. The... 
MEDICINE, GENERAL & INTERNAL | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | EMTRICITABINE | EFAVIRENZ | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | INITIAL TREATMENT | PHASE-3 | ANTIRETROVIRAL-NAIVE ADULTS | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | Male | RNA, Viral - blood | HIV-1 - genetics | Lamivudine - adverse effects | Young Adult | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Lamivudine - therapeutic use | Aged, 80 and over | Adult | Female | HIV Infections - drug therapy | Aged | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | Research | HIV (Viruses) | Drug therapy | Abacavir | Integrase | Emtricitabine | Antiretroviral drugs | Lamivudine | Infections | Lymphocytes T | Ribonucleic acid--RNA | Efavirenz | Manuscripts | Dreams | CD4 antigen | Tenofovir | Sleep disorders | Antiretroviral agents | Human immunodeficiency virus--HIV | Anxiety | Mutation | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens
by Anastos, Kathryn and Lu, Dalian and Shi, Qiuhu and Tien, Phyllis C and Kaplan, Robert C and Hessol, Nancy A and Cole, Steven and Vigen, Cheryl and Cohen, Mardge and Young, Mary and Justman, Jessica
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2007, Volume 45, Issue 1, pp. 34 - 42
BACKGROUND:The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well... 
Low-density lipoprotein | Women | Highly active antiretroviral therapy | Lipids | High-density lipoprotein | INFECTIOUS DISEASES | lipids | high-density lipoprotein | BODY-COMPOSITION | IMMUNOLOGY | INSULIN SENSITIVITY | PROTEASE INHIBITORS | low-density lipoprotein | DIABETES-MELLITUS | NAIVE SUBJECTS | DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | PLASMA-CONCENTRATIONS | highly active antiretroviral therapy | INFECTED PATIENTS | LOPINAVIR/RITONAVIR | women | Cholesterol - blood | Didanosine - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Hispanic Americans - statistics & numerical data | Nevirapine - adverse effects | Tenofovir | Adenine - therapeutic use | Stavudine - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Dideoxynucleosides - adverse effects | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Organophosphonates - adverse effects | HIV Protease Inhibitors - therapeutic use | HIV-1 | Didanosine - therapeutic use | Multivariate Analysis | Lipoproteins, HDL - blood | United States | HIV Seropositivity - drug therapy | Nevirapine - therapeutic use | Lamivudine - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Stavudine - adverse effects | Lipids - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | HIV Seronegativity | Nelfinavir - therapeutic use | Fasting | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | European Continental Ancestry Group - statistics & numerical data | Benzoxazines - therapeutic use | Nelfinavir - adverse effects | African Continental Ancestry Group - statistics & numerical data | Triglycerides - blood | HIV Infections - drug therapy | Indinavir - adverse effects | Lipoproteins, LDL - blood | HIV Infections - metabolism | Indinavir - therapeutic use | Measurement | Complications and side effects | Dosage and administration | Blood lipids | Health aspects | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pharmacogenetics: The right drug for you
by Drew, Liam
Nature, ISSN 0028-0836, 09/2016, Volume 537, Issue 7619, pp. S60 - S62
Drug-Related Side Effects and Adverse Reactions - prevention & control | Humans | Warfarin - metabolism | Warfarin - adverse effects | Male | Antidepressive Agents - metabolism | Warfarin - administration & dosage | Warfarin - therapeutic use | Evidence-Based Medicine - trends | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Pharmacogenetics - trends | Purine-Pyrimidine Metabolism, Inborn Errors - complications | Mercaptopurine - therapeutic use | Drug Hypersensitivity - enzymology | Drug-Related Side Effects and Adverse Reactions - genetics | Drug Hypersensitivity - genetics | Mercaptopurine - metabolism | Succinylcholine - adverse effects | Dideoxynucleosides - adverse effects | Drug Hypersensitivity - complications | Child | HLA-B Antigens - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications | Pharmacogenetics - methods | HIV Infections - genetics | Mercaptopurine - administration & dosage | Mercaptopurine - adverse effects | Purine-Pyrimidine Metabolism, Inborn Errors - enzymology | Antidepressive Agents - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Genetic Testing - utilization | Purine-Pyrimidine Metabolism, Inborn Errors - genetics | Precision Medicine - trends | Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Antidepressive Agents - administration & dosage | HIV Infections - drug therapy | Antidepressive Agents - adverse effects | Primaquine - adverse effects | Precision Medicine - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury
by Kaniwa, Nahoko and Saito, Yoshiro
Journal of Human Genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
Rare but severe adverse drug reactions (ADRs) are an important issue in drug development and in the proper usage of drugs during the post-approval phase. The... 
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | HLA CLASS-I | TOXIC EPIDERMAL NECROLYSIS | CLASS-II GENOTYPE | GENETIC SUSCEPTIBILITY | RISK-FACTOR | GENETICS & HEREDITY | GENOME-WIDE | HLA-B-ASTERISK-1502 ALLELE | JAPANESE PATIENTS | STEVENS-JOHNSON-SYNDROME | ABACAVIR HYPERSENSITIVITY | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial
by Allison Martin and Mark Bloch and Janaki Amin and David Baker and David A. Cooper and Sean Emery and Andrew Carr and STEAL Study Grp
Clinical Infectious Diseases, ISSN 1058-4838, 11/2009, Volume 49, Issue 10, pp. 1591 - 1601
Background. There are 2 once-daily, fixed-dose-combination, dual–nucleoside analogue tablets: tenofovir 300 mg–emtricitabine 200 mg (TDF-FTC) and abacavir 600... 
Myocardial infarction | HIV/AIDS | Antiretrovirals | HIV | Protease inhibitors | HDL lipoproteins | AIDS | Experimentation | Bone density | Cholesterols | Virology | INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE INHIBITORS | MYOCARDIAL-INFARCTION | RISK | MICROBIOLOGY | IMMUNOLOGY | HIV-INFECTED PATIENTS | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Dideoxynucleosides | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | HLA-B Antigens - genetics | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - complications | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Usage | Drug therapy, Combination | HIV (Viruses) | Drug therapy | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights